



Nexia Biotechnologies Ltd.
P.O. Box 187, Jean-Talon Branch
Montreal, Quebec H1S 2Z2
www.nexiabiotech.com

Edmonton, Alberta, Canada, February 8, 2008: Nexia Biotechnologies Ltd. ("Nexia") (CNQ: NXBL) announced today that it has acquired ownership of an aggregate of 19,765,032 common shares of Inflazyme Pharmaceuticals Ltd. ("Inflazyme") (NEX: IZP.H) representing 15.1% of the issued and outstanding common shares of Inflazyme. Nexia acquired ownership of 19,765,032 Inflazyme shares at a price of Cdn.\$400,000 (Cdn.\$0.02 per share) pursuant to a private share purchase agreement entered into effective February 6, 2008. Nexia does not currently own any other securities of Inflazyme.

Nexia acquired the Inflazyme shares for investment purposes. Nexia may from time to time acquire additional securities of Inflazyme, dispose of some or all of the existing or additional securities it holds or will hold, or may continue to hold its current position.

ABOUT NEXIA

For more information, please visit Nexia's website at www.nexiabiotech.com. Nexia's continuous disclosure documents can be accessed through Nexia's securities filings at www.sedar.com.

CONTACT INFORMATION

David L. Tonken, President, Chief Executive Officer and Chairman of the Board

Email: tonken@icrossroads.com

Telephone: (780) 486-2317